Brian Lehmann
Last active: 9/15/2015

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW, Lehmann BD, Terrian DM, Basecke J, Stivala F, Libra M, Evangelisti C, Martelli AM
Adv Enzyme Regul. 2007 47: 64-103

PMID: 17382374 · PMCID: PMC2696319 · DOI:10.1016/j.advenzreg.2006.12.013

MeSH Terms (15)

Animals Antineoplastic Agents Cell Line, Tumor Drug Delivery Systems Drug Resistance, Neoplasm Extracellular Signal-Regulated MAP Kinases Hematologic Neoplasms Mice Mitogen-Activated Protein Kinase Kinases Phosphatidylinositol 3-Kinases Phosphoinositide-3 Kinase Inhibitors Proto-Oncogene Proteins c-akt raf Kinases Signal Transduction Tumor Suppressor Protein p53

Connections (1)

This publication is referenced by other Labnodes entities: